Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Jul 11;18(1):144.
doi: 10.1186/s12872-018-0882-5.

Deleterious effects of catecholamine administration in acute heart failure caused by unrecognized Takotsubo cardiomyopathy

Michael Dandel  1   2 , Roland Hetzer  3   4
Affiliations
Comment

Deleterious effects of catecholamine administration in acute heart failure caused by unrecognized Takotsubo cardiomyopathy

Michael Dandel et al. BMC Cardiovasc Disord. .

Abstract

The potential life-threatening consequences of catecholamine use for emergency circulatory support in Takotsubo cardiomyopathy-related acute heart failure is a major challenge in cardiovascular emergences. In their recent work in BMC Cardiovascular Disorders Ansari U. et al. demonstrated the harmful effects of catecholamines on the outcome of patients with Takotsubo cardiomyopathy. Concerning this matter we emphasize the usefulness of speckle-tracking-derived echocardiography for early recognition of an acute phase of a Takotsubo syndrome in order to avoid the deleterious effects of a catecholamine therapy in patients with Takotsubo-associated acute heart failure.

Keywords: Acute heart failure; Catecholamines; Diagnosis; Etiopathogenesis; Myocardial infarction; Speckle-tracking echocardiography; Takotsubo cardiomyopathy.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Comment on

References

    1. Ansari U, El-Battrawy I, Fastner C, et al. Clinical outcomes associated with catecholamine use in patients diagnosed with Takotsubo cardiomyopathy. BMC Cardiovasc Disord. 2018;18(1):54. doi: 10.1186/s12872-018-0784-6. - DOI - PMC - PubMed
    1. Akashi YJ, Nakazawa K, Sakakibara M, et al. The clinical features of takotsubo cardiomyopathy. QJM. 2003;96(8):563–573. doi: 10.1093/qjmed/hcg096. - DOI - PubMed
    1. Borchert T, Hübscher D, Guessoum CI, et al. Catecholamine-dependent β-adrenergic signaling in a pluripotent stem cell model of TakotsuboCardiomyopathy. J Am Coll Cardiol. 2017;70(8):975–991. doi: 10.1016/j.jacc.2017.06.061. - DOI - PubMed
    1. Dandel M, Lehmkuhl HB, Schmidt G, et al. Striking observations during emergency catecholamine treatment of cardiac syncope in a patient with initially unrecognized Takotsubo cardiomyopathy. Circ J. 2009;73:1543–1546. doi: 10.1253/circj.CJ-08-0256. - DOI - PubMed
    1. Dandel M, Lehmkuhl H, Knosalla C, Hetzer R. Left ventricular wall motion abnormality and myocardial dysfunction in stress cardiomyopathy: new pathophysiological aspects suggested by echocardiography. Int J Cardiol. 2009;135(2):40–43. doi: 10.1016/j.ijcard.2008.03.070. - DOI - PubMed